MET and hepatocellular carcinoma: Nilotinib inhibits MYC and NOTCH1 expression in HCC cell lines, inhibits the growth of xenograft tumors in mice, and inhibits the formation of liver tumors in animals harboring MET and catenin β1 transposons, lowering MYC and NOTCH1 levels in tumors [22].